Fig 1: Correlation between plasma VEGFR2 and TG/HDL-chol levels in the entire hemodialysis group. VEGFR2, vascular endothelial growth factor receptor 2; TG, triglycerides; HDL-chol, high density lipoprotein cholesterol.
Fig 2: ROC curve of VEGFR2 in the prognosis of dyslipidemia in patients receiving hemodialysis. VEGFR2, vascular endothelial growth factor receptor 2; ROC, receiver operating characteristic.
Fig 3: Correlation between plasma VEGFR2 and plasma RAGE expression levels in the entire hemodialysis group. VEGFR2, vascular endothelial growth factor receptor 2; RAGE, receptor for advanced glycation end-products.
Fig 4: Effect of CMC-AgNPs on VEGFR-2 (pg/mL) in HepG2 cells compared to taxol (A); effect of CMC-AgNPs on caspase-8 and caspase-9 (ng/mL) in HepG2 cells compared to taxol (B). The results are shown as the mean ± SD. * Significantly different from the control (HepG2 cells) group at p < 0.0001.
Fig 5: Comparison of plasma VEGFR2 concentration in HD patients and controls. VEGFR2, vascular endothelial growth factor receptor 2; HD, hemodialysis.
Supplier Page from Abcam for Human VEGF Receptor 2 ELISA Kit